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Edited by Vladimir SkulachevAbstract We demonstrate expression and coordinate induction
of PPARc and lipogenic enzymes (HMG-CoA synthase, HMG-
CoA reductase and fatty acid synthase) in a murine lung alveolar
carcinoma cell line (Line 1) treated with the PPARc agonist
troglitazone (TRO) [0–100 lM]. We postulate that TRO in-
duces a shift in cellular energy metabolism towards fatty acid
oxidation (b-oxidative respiration). Accordingly, co-treatment
with TRO [30 lM] and increasing concentrations of trimetazi-
dine (TMZ) [0.1–3 mM], an inhibitor of b-oxidation, results in
a dose dependent decrease cellular ATP levels and a dose depen-
dent induction of apoptosis. These ﬁndings, suggest that inhibi-
tion of b-oxidative respiration is a therapeutic window
associated with the cancer chemo-preventive activity of PPARc
agonists.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The peroxisome proliferator activated receptor gamma
(PPARc) is a central regulator of adipogenesis and adipo-
cyte diﬀerentiation [1,2]. As such PPARc agonists notably
the thiazolidinediones (TZDs), induce terminal diﬀerentia-
tion of liposarcoma cell lines and interestingly exert antipro-
liferative eﬀects on a broad spectrum of unrelated cancer cell
lines [3]. The antiproliferative eﬀects of TZDs have been
demonstrated in multiple contexts, implicating a PPARc
dependent modulation of cell cycle regulatory proteins [re-
viewed in 1]. There is equally compelling evidence in supportAbbreviations: PPARc, peroxisome proliferator activated receptor
gamma; TZD, thiazolidinediones; ATP, adenosine triphosphate; ROS,
reactive oxygen species; NADPH2, methylenetetrahydrofolate reduc-
tase; HMG-CoA, hydroxymethylglutaryl CoA; TRO, troglitazone;
TMZ, trimetazidine; PDH, pyruvate dehydrogenase; ACL, ATP
citrate lysase
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liferative eﬀects of a TZD on PPARc/ cell lines [4]. In
this context, TZDs were reported to inhibit protein transla-
tion by phosphorylating and inactivating the a-subunit of
eukaryotic initiation factor (elf2), through depleting intracel-
lular calcium stores and activating protein kinase R [4].
Contradictory evidence in support of a tumor promoting
activity of PPARc has been observed in Min (APC /+)
mice, with a genetic predisposition to adenomatous polypo-
sis coli (APC) [5,6]. However an overwhelming body of
scientiﬁc evidence favors the use of PPARc agonists as
chemo-preventive agents in patients at risk of developing
various types of cancers [3,7].
A better established property of TZDs, is their clinical
utility as insulin sensitizing agents in the treatment of type
II diabetes [8]. This PPARc dependent property involves
the transcriptional induction of lipogenic factors and atten-
dant increases in glucose uptake, to subtend the require-
ments for reducing equivalents (methylenetetrahydrofolate
reductase, NADPH2) and carbon moieties (acetyl-CoA) for
fatty acid and sterol synthesis [9–11], at the expense of redox
control or energy production. Because increased glucose
metabolism is a fundamental adaptation in hyperprolifera-
tive states such a cancer [12,13], we postulated that a
TZD induced metabolic ﬂux contributed to its anticancer
activity. Using a murine lung alveolar carcinoma cell model
(Line 1), we demonstrate that treatment with the TZD, trog-
litazone (TRO), leads to the transcriptional induction of lip-
ogenic enzymes, increases glucose consumption to support
lipogenesis and shifts cellular energy metabolism towards
b-oxidative respiration. As such, TRO sensitized Line 1 tu-
mor cells to metabolic interference with trimetazidine
(TMZ), an inhibitor of b-oxidative respiration. These ﬁnd-
ings suggest that inhibition of b-oxidative respiration is
potentially a therapeutic window associated with the cancer
chemo-preventive activity of PPARc agonists.2. Materials and methods
The PPARc agonist, troglitazone (Calbiochem) was reconstituted
in dimethyl sulfoxide (DMSO) to obtain a 10 mM stock solution
and stored at 80 C. The chemical inhibitor of sterol and fatty
acid synthesis, Cerelunin (Calbiochem) was reconstituted in DMSO
to obtain a 20 mM stock solution and stored at 4 C. Trimetazidine
dihyrochloride (Laboratoires Servier, France), an inhibitor of the
terminal enzyme in b-oxidation, long chain 3-keto-acyl thiolase,
was freshly reconstituted in water to obtain a 0.1 M stock solution.blished by Elsevier B.V. All rights reserved.
Fig. 1. Expression and dose-dependent induction of PPARc and
lipogenic enzymes (HMG-CoA synthase, HMG-CoA reductase and
fatty acid synthase) in Line 1 tumor cells treated with TRO [0–100 lM]
for 24 h. Gene expression was assessed by RT-PCR, using gene speciﬁc
primers and equal sample loading was conﬁrmed by exponential
ampliﬁcation of b-actin.
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The murine lung alveolar carcinoma cell line, Line 1, was generously
provided by Dr. Edith Lord. Line 1 cells cultured in DMEM supple-
mented with 10% FBS and 1% penicillin/streptomycin, and maintained
at 37 C in a 95% humid atmosphere, with 5% CO2.
2.2. Regulation of PPARc and lipogenic enzymes by TRO in Line 1 cells
Line 1 cells treated for 24 h with drug vehicle or TRO (0–100 lM)
were assessed for the expression of PPARc and various lipogenic en-
zymes by RT-PCR. Brieﬂy, total RNA was obtained from Line 1 tu-
mor cells using the RNAeasy kit (Qiagen), following the
manufacturers instructions. 1 lg of total RNA thus obtained was re-
verse transcribed using Superscript II (Invitrogen) and diluted 5-fold
in RNAase free water. 2 ll of the cDNA diluent, admixed with 2 ll
of reverse-forward primer pairs (50 pg) and 16 ll of the 1· PCR mas-
terrmix (Eppendorf), was ampliﬁed for PPARc (5 0-TTT GAG CTC
TTC TGA CAG GAC TGT GTG ACA G-3 0 and 5 0-TTT GAG
CTC ATA AGG TGG AGA TGC AGG TTC-3 0), hydroxymethyl-
glutaryl CoA (HMG-CoA) reductase (5 0-GGG ACG GTG ACA
CTT ACC ATC TGT ATG ATG-3 0 and 5 0-ATC ATC TTG GAG
TAA AAC TGC CA- 3 0), HMG-CoA synthase (5 0-TAT GAT GGT
GTA GAT GCT GGG AAG TAT ACC-3 0 and 5 0-TAA GTT CTT
CTG TGC TTT TCA TCC AC-3 0) and fatty acid synthase (5 0-GGC
TTT GGC CTG GAA CTG GCC CGG TGG CT-3 0 and 5 0-TCG
AAG GCT ACA CAA GCT CCA AAA GAA TA-3 0), under the fol-
lowing conditions; initial denaturing at 95 C for 2 min, followed by 30
cycles of denaturing at 95 C for 45 s, annealing at 55 C for 45 s, and
extension at 72 C for 1 min; and a ﬁnal extension of 72 C for 7 min.
The expression level of b-actin (5 0-GAGCTATGAGCTGCCTGACG-
3 0 and 5 0-AGCACTTGCGGTGCACGATG-30) was assessed under
identical conditions to normalize for RNA loading across all samples.
2.3. Assessment of glucose uptake, correlated to ROS and ATP levels
100000 Line 1 tumor cells were seeded in 6 well plates and treated
with increasing concentrations of TRO [0–100 lM] for 24 h. Cellular
uptake of glucose was assessed by measuring residual glucose in cul-
ture media with the glucose determination kit (Sigma). Cellular aden-
osine triphosphate (ATP) levels were measured with the ATP
determination kit (Molecular Probes) per the manufacturers instruc-
tions. The total number of viable cells was assessed by manually count-
ing Trypan blue negative cells and the cell count was used to normalize
for glucose uptake and cellular ATP content across treatment groups.
2.4. Assessment of cellular proliferation and apoptosis
Cellular incorporation of radioactive thymidine was used as an in-
dex of cell proliferation. Brieﬂy, 6 h after adding drug agents, cultures
of 50000 cells/well in 96-well plates (Falcon) were labeled with 8 mCi/
ml [3H]Thymidine (New England Nuclear, Boston, MA, USA). At the
end of the 24-h incubation period, cellular DNA was precipitated, pel-
leted and re-dissolved in NaOH. Radioactivity was determined by li-
quid scintillation spectrometry. Cellular apoptosis was assessed with
the Annexin V-PE Apoptosis detection kit I (BD Pharmingen) per
the manufacturers instructions.Fig. 2. Increased glucose consumption as a result of Troglitazone
induced lipogenesis. Line 1 tumor cells were treated with TRO
[0–100 lM] for 24 h, in the absence (white bars) or in the presence
(grey bars) of cerulenin [20 lM], an inhibitor of sterol and fatty acid
synthesis. Glucose concentration in an aliquot of culture medium was
assessed using the Toluidine-O method and normalized to the cell
count. The results represent means ± S.E. of three independent
experiments. Note. Glucose uptake/utilization is inversely related to
the residual glucose concentration in the culture medium. *Statistically
signiﬁcant diﬀerences (P < 0.05) between TRO ± cerulenin.3. Results and discussion
3.1. Expression and regulation of PPARc and lipogenic enzymes
in Line 1 cells
PPARc modulates lipid synthesis and storage by regulating
the transcription of lipogenic enzymes [14], intracellular buﬀer
systems and membrane transporters (eﬄux systems) [15]. The
auto-regulation of PPARc expression and its endogenous acti-
vation by polyunsaturated fatty acids and eicosanoids notably
prostaglandin J2 [16], is suggestive of a central component of
an integral regulatory loop. In the Line 1 tumor cell model,
we demonstrate expression and coordinate induction of
PPARc, HMG-CoA synthase, HMG-CoA reductase and fatty
acid synthase transcripts, in response to 24-h treatment with
the synthetic PPARc agonist, TRO (Fig. 1).3.2. Troglitazone induced glucose consumption is blunted by the
chemical inhibitor of sterol and fatty acid synthesis –
cerulenin
Sterol and fatty acid synthesis requires stoichiometric
amounts of reducing equivalents (NADPH2) and carbon moi-
eties (acetyl-CoA). NADPH2 demand is primarily met by
increasing the ﬂux of glucose through the pentose phosphate
shunt [9], while acetyl-CoA is derived from the conversion of
pyruvate or citrate to acetyl-coA, by pyruvate dehydrogenase
(PDH) and ATP citrate lysase (ACL), respectively [11]. It is
equally established that the physiologic role of insulin in the
regulation of glucose metabolism, hinges on the coordinate
induction of PDH, ACL and acetyl-coA-carboxylase, the rate
limiting enzyme in fatty acid synthesis [17]. Similarly, the phar-
macologic property of TZDs in the treatement of type II dia-
betes hinges on the induction of lipogenesis. Accordingly, we
demonstrate a dose and time dependent increase in glucose
consumption in Line 1 cells treated with TRO and a blunting
of this response by cerulenin [20 lM], a chemical inhibitor of
sterol and fatty acid synthesis (Fig. 2).
3.3. The decrease in proliferation of Line 1 tumor cells exposed
to TRO does not result from altered ROS or ATP levels
Given the importance of glucose in energy metabolism and
redox control (NADPH2 reducing power), especially in hy-
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the metabolic ﬂux induced by TRO resulted in a metabolic
‘‘crisis’’ that compromised cellular proliferation, amongst
other cellular functions. TRO induces a dose dependent de-
crease in cellular proliferation (Fig. 3A). The eﬀects of TRO
were primarily cytostatic, based on trypan blue exclusion
and the absence of apoptotic cell death in the 0.1–30 lM dose
range, relative to controls (Fig. 3B). Furthermore, TRO did
not alter ROS (Fig. 3C) or ATP (Fig. 3D) levels.
3.4. TRO sensitizes Line 1 tumor cells to metabolic interference
with TMZ, an inhibitor of b-oxidation
We thus postulated that the induction of fatty acid synthesis
by TRO and a shift in cellular energy metabolism towards
fatty acid oxidation (b-oxidative respiration) compensatedFig. 3. Troglitazone induced proliferation arrest does not result from alteratio
by cellular incorporation of radioactive thymidine. The results represent mean
by annexin V-PE staining after 24 h drug exposure. Apoptotic cells are gated
sensitive, cell permeable ﬂuorescent probe DCF [0.4 lM] for 15 min and asse
results indicate mean ﬂuorescence of 10000 events (cells). (D) Cellular ATP
and normalized to cell number. The results represent means ± S.E. of three in
treatment groups are indicated in the graphs.for the diversion of glucose from redox control and energy
metabolism. Theoretically, from the standpoint of energy
yield, 2.5 times more ATP is generated from oxidizing a mol-
ecule of 6-carbon chain fatty acid compared to a molecule of
glucose, although approximately 5 times more molecular oxy-
gen is utilized and consequently more reactive oxygen species
(ROS) generated in the process [18]. Conceivably, because
fatty acids are natural uncouplers of the respiratory chain
[19–21] and PPARc upregulates uncoupling protein expression
in parallel with the induction of b-oxidative respiration [22],
cellular redox state and energetics are maintained within the
physiologic range. To test this hypothesis, Line 1 cells were ex-
posed to increasing concentrations of an inhibitor b-oxidative
respiration, TMZ [0.1–3 mM], plus 30 lM TRO. Trimetazi-
dine had a marginal eﬀect on cellular proliferation in thens in redox and energy balance. (A) Cellular proliferation was assessed
s ± S.E. of three independent experiments. (B) Apoptosis was assessed
in M2. (C) ROS levels were assessed by labeling cells with the redox
ssing for spectral changes with a ﬂuorescence activated cell sorter. The
levels were determined with the ATP detection kit (Molecular Probes)
dependent experiments. Statistically signiﬁcant diﬀerences (P < 0.05) in
Fig. 4. Troglitazone induces a shift cellular energy metabolism towards b-oxidative respiration and sensitizes Line 1 tumor cell to metabolic
interference with TMZ (an inhibitor of b-oxidation. (A) Cellular proliferation assessed by cellular incorporation of radioactive thymidine. The results
represent means ± S.E. of three independent experiments. (B) Apotosis was assessed after 36 h of drug exposure by Annexin V-PE staining.
Apoptotic cells are gated in the M2. (C) Cellular ATP levels were determined after a 24 h drug exposure. The results represent means ± S.E. of three
independent experiments. Statistically signiﬁcant diﬀerences (P < 0.05) between treatment groups are indicated in the graphs.
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decrease in cellular proliferation. Co-treatment with 30 lM
TRO did not result in an additive or synergistic inhibition of
cellular proliferation across all treatment groups (Fig. 4A).
Interestingly, TMZ dose dependently induced apoptosis and
co-treament with 30 lM TRO resulted in an additive increase
in the population of apoptotic cells across all treatment groups
(Fig. 4B). In parallel, TMZ induced a dose-dependent decreasein cellular ATP levels and co-treatment with 30 lM TRO
potentiated the downshift in cellular ATP levels (Fig. 4C).4. Conclusion
Taken together, these results suggest that PPARc agonists
shift the energy metabolism of cancer cells towards b-oxidative
V.B. Andela et al. / FEBS Letters 579 (2005) 1765–1769 1769respiration and thereby, open a window for therapeutic inter-
vention with inhibitors of b-oxidative respiration in cancer
chemo-preventive interventions. This compelling hypothesis
warrants further testing in various in vitro and in vivo labora-
tory models of cancer.
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